Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cycloserine

FDA-approved product (capsule, oral), marketed as Seromycin.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cycloserine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Extrapulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB01

Repurposing investigation

Cycloserine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae15.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis5.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 2 of 4 lab records
  • M. tuberculosis: measured active in 0 of 2 lab records
Open Cycloserine in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cycloserine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder

    NCT00842309 · start 2008-11

    Registered record
    Registry ID
    NCT00842309
    Conditions
    Body Dysmorphic Disorder
    Interventions
    d-cycloserine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2008-11
    Completion
    2018-08
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBody Dysmorphic Disorder
    Interventiond-cycloserine; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Drug Discrimination in Methadone-Maintained Humans Study 2

    NCT00733239 · start 2008-08

    Registered record
    Registry ID
    NCT00733239
    Conditions
    Opioid Dependence
    Interventions
    2-4 of the drugs listed below
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08
    Completion
    2010-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Dependence
    Intervention2-4 of the drugs listed below
    PhasePhase 1
    Registry statusCompleted

  • Food Exposure Therapy in Anorexia Nervosa

    NCT00755820 · start 2008-01

    Registered record
    Registry ID
    NCT00755820
    Conditions
    Anorexia Nervosa
    Interventions
    Exposure Therapy + D-Cycloserine; Exposure Therapy + Placebo; Supportive Psychotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-01
    Completion
    2012-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnorexia Nervosa
    InterventionExposure Therapy + D-Cycloserine; Exposure Therapy + Placebo; Supportive Psychotherapy
    PhaseNot recorded
    Registry statusCompleted

  • D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder

    NCT00864123 · start 2008-01

    Registered record
    Registry ID
    NCT00864123
    Conditions
    Obsessive-compulsive Disorder
    Interventions
    Cognitive-behavioral therapy; D-cycloserine; Placebo pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-compulsive Disorder
    InterventionCognitive-behavioral therapy; D-cycloserine; Placebo pill
    PhasePhase 2
    Registry statusCompleted

  • The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly

    NCT01361633 · start 2008-01

    Registered record
    Registry ID
    NCT01361633
    Conditions
    Treatment; Placebo
    Interventions
    d-cycloserine; Sugar Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-02
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment; Placebo
    Interventiond-cycloserine; Sugar Pill
    PhasePhase 2
    Registry statusCompleted

  • RCT of CBT Combined With D-Cycloserine for Treating PTSD

    NCT00452231 · start 2007-02

    Registered record
    Registry ID
    NCT00452231
    Conditions
    Post-Traumatic Stress Disorder
    Interventions
    D-cycloserine; Cognitive-Behavioral Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2007-02
    Completion
    2008-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Traumatic Stress Disorder
    InterventionD-cycloserine; Cognitive-Behavioral Therapy
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • D-cycloserine for Major Depressive Disorder

    NCT00408031 · start 2007-01

    Registered record
    Registry ID
    NCT00408031
    Conditions
    Major Depressive Disorder
    Interventions
    D-cycloserine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2010-05
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionD-cycloserine
    PhasePhase 2
    Registry statusCompleted

  • A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD

    NCT00371176 · start 2006-10

    Registered record
    Registry ID
    NCT00371176
    Conditions
    Combat Disorders; Stress Disorders, Post-Traumatic
    Interventions
    Exposure therapy; D-Cycloserine; Placebo pill
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-10
    Completion
    2012-07
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCombat Disorders; Stress Disorders, Post-Traumatic
    InterventionExposure therapy; D-Cycloserine; Placebo pill
    PhaseNot applicable
    Registry statusCompleted

  • D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

    NCT00356278 · start 2006-09

    Registered record
    Registry ID
    NCT00356278
    Conditions
    Stress Disorder, Post Traumatic
    Interventions
    D-Cycloserine; Alprazolam; Virtual Reality Exposure Therapy; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2006-09
    Completion
    2014-06
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorder, Post Traumatic
    InterventionD-Cycloserine; Alprazolam; Virtual Reality Exposure Therapy; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain

    NCT00301080 · start 2006-02

    Registered record
    Registry ID
    NCT00301080
    Conditions
    Neurotoxicity; Pain; Breast Cancer
    Interventions
    D-cycloserine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-02
    Completion
    2008-05
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurotoxicity; Pain; Breast Cancer
    InterventionD-cycloserine; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia

    NCT00455702 · start 2004-07

    Registered record
    Registry ID
    NCT00455702
    Conditions
    Schizophrenia
    Interventions
    d-cycloserine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-07
    Completion
    2007-04
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventiond-cycloserine
    PhasePhase 4
    Registry statusCompleted

  • High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis

    NCT00513396 · start 2004-01

    Registered record
    Registry ID
    NCT00513396
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Isoniazid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2004-01
    Completion
    2006-12
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIsoniazid; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder

    NCT00126282 · start 2003-12

    Registered record
    Registry ID
    NCT00126282
    Conditions
    Obsessive-Compulsive Disorder
    Interventions
    behavior therapy; D-Cycloserine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-12
    Completion
    2007-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObsessive-Compulsive Disorder
    Interventionbehavior therapy; D-Cycloserine
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

    NCT00222235 · start 2000-01

    Registered record
    Registry ID
    NCT00222235
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    d-cycloserine; glycine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2000-01
    Completion
    2004-06
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    Interventiond-cycloserine; glycine; placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted